This study is being done to see if daratumumab is safe and effective in the treatment of
proliferative glomerulonephritis with monoclonal immune deposits (PGNMID) and C3
glomerulopathy associated with monoclonal gammopathy (C3GN). This is an inflammatory disease
in the kidney due to the production of abnormal proteins. There are no known standard
effective treatments for patients with PGNMID and C3GN secondary to monoclonal gammopathy.
These diseases are caused by abnormal production of proteins (monoclonals) by abnormal
clones. Daratumamb has been shown to be effective in treating patients with multiple myeloma
a disease which also caused by over production of monoclonal proteins from abnormal clones.
Everyone in this study will receive daratumumab.